Tema Etfs LLC Acquires Shares of 890,548 Mereo BioPharma Group plc (NASDAQ:MREO)

Tema Etfs LLC acquired a new position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 890,548 shares of the company's stock, valued at approximately $3,117,000. Mereo BioPharma Group comprises about 1.3% of Tema Etfs LLC's portfolio, making the stock its 25th biggest holding. Tema Etfs LLC owned about 0.57% of Mereo BioPharma Group as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MREO. Janus Henderson Group PLC increased its stake in Mereo BioPharma Group by 38.7% during the 4th quarter. Janus Henderson Group PLC now owns 17,122,563 shares of the company's stock worth $59,843,000 after purchasing an additional 4,776,697 shares in the last quarter. Rock Springs Capital Management LP increased its position in shares of Mereo BioPharma Group by 0.7% during the fourth quarter. Rock Springs Capital Management LP now owns 9,599,170 shares of the company's stock worth $33,597,000 after acquiring an additional 65,000 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Mereo BioPharma Group during the fourth quarter worth $1,729,000. HealthInvest Partners AB lifted its position in Mereo BioPharma Group by 95.0% in the 4th quarter. HealthInvest Partners AB now owns 390,000 shares of the company's stock valued at $1,373,000 after acquiring an additional 190,000 shares in the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new position in Mereo BioPharma Group in the 4th quarter worth $788,000. Institutional investors and hedge funds own 62.83% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. JPMorgan Chase & Co. initiated coverage on shares of Mereo BioPharma Group in a research report on Thursday, March 27th. They set an "overweight" rating and a $7.00 price target on the stock. Finally, Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, May 13th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Mereo BioPharma Group has an average rating of "Buy" and a consensus price target of $7.71.

Mereo BioPharma Group Stock Down 1.1%

Shares of MREO stock traded down $0.03 during trading on Friday, reaching $2.26. 255,173 shares of the company's stock were exchanged, compared to its average volume of 1,114,446. Mereo BioPharma Group plc has a twelve month low of $1.58 and a twelve month high of $5.02. The stock has a market capitalization of $358.55 million, a PE ratio of -32.21 and a beta of 0.53. The firm's fifty day moving average price is $2.29 and its 200-day moving average price is $2.93.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). As a group, analysts anticipate that Mereo BioPharma Group plc will post -0.03 EPS for the current fiscal year.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.